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Introduction: The purpose of this study was to examine and compare the conjunctival irritation 
(congestion, swelling, and discharge) of topical bimatoprost ophthalmic solution 0.01% and 
bimatoprost ophthalmic solution 0.03% in rabbits.
Methods: Six healthy New Zealand White rabbits were treated with either bimatoprost 0.01% 
or bimatoprost 0.03% (3 animals/group). One dose (2 drops/dose) of study medication was 
administered to the right eye of each animal every 30 minutes for 4.5 hours. Approximately 
1 hour after the last dose, conjunctival irritation was assessed using a slit-lamp biomicroscope 
to individually evaluate conjunctival congestion, swelling, and discharge.
Results: The mean conjunctival congestion, swelling and discharge scores for bimatoprost 
0.03% were 1.67, 0.33 and 0.33, respectively, and for bimatoprost 0.01% were 2.00, 0.33 and 
1.33, respectively.
Conclusions: Despite the lower drug concentration of the 0.01% formulation, bimatoprost 
0.01% does not reduce conjunctival irritation, including conjunctival congestion, swelling, 
and discharge, in rabbits compared to bimatoprost 0.03%. Further studies would be needed to 
determine whether the increase in the mean conjunctival congestion and discharge scores may 
be attributed to the increased BAK concentration in the bimatoprost 0.01% formulation.
Keywords: bimatoprost, conjunctiva, ocular toxicity, preclinical, prostaglandin analog, 
rabbits
Introduction
Reduction of elevated intraocular pressure (IOP) is the only modifiable risk factor for 
glaucoma, the second leading cause of vision loss worldwide.1 Prostaglandin analogs 
are one class of drugs commonly used to reduce IOP. Bimatoprost 0.03% (Lumigan®; 
Allergan, Inc., Irvine, CA, USA), one such prostaglandin analog,2,3 reduces IOP by 
6.5 to 8.9 mmHg in patients with open-angle glaucoma or ocular hypertension.4–6 
However, this agent is not without side effects; conjunctival congestion is the most 
frequent adverse event of bimatoprost, affecting 45% of patients and accounting for 
discontinuation of therapy in 3% of patients.7
A new formulation of bimatoprost has been developed that has a lower concen-
tration of drug (0.01%; Lumigan; Allergan, Inc.) in an attempt to improve the safety 
profile of this agent. The new formulation also has a 4-fold increase in the amount 
of benzalkonium chloride (BAK) (0.02%) compared to the original formulation 
(0.005%). BAK is a preservative commonly used in topical ophthalmic agents, but 
evidence suggests that it may also facilitate drug delivery. Specifically, it has been 
shown to increase transcorneal drug penetration in rabbits.8 This characteristic can Clinical Ophthalmology 2010:4 78
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potentially be explained by a loss of tight junctions in the 
corneal epithelium, which could improve corneal penetra-
tion. In fact, McCarey and Edelhauser demonstrated that 
eyes treated with topical drugs containing BAK display a 
preferential loss of epithelial tight junctions.9 However, the 
presence of BAK in ophthalmic preparations may also cause 
ocular toxicity, as demonstrated by numerous in vitro and in 
vivo studies.10–15 Thus, the increase in BAK concentration 
of the new bimatoprost formulation may have implications 
not only for drug penetration but also for drug safety. The 
goal of the current study was to examine and compare con-
junctival irritation (congestion, swelling, and discharge) of 
topical ocular bimatoprost 0.01% and bimatoprost 0.03% 
in rabbits.
Methods
Six healthy New Zealand White rabbits were divided into 
2 treatment groups (3 animals per group): commercially 
available bimatoprost ophthalmic solution 0.01% (Lumigan 
0.01%, Allergan Inc., Ontario, Canada) and bimatoprost 
ophthalmic solution 0.03% (Lumigan 0.03%, Allergan Inc., 
Irvine, CA). One dose of the bimatoprost ophthalmic solu-
tions (2 drops/dose) was administered to the right eye of 
each animal every 30 minutes for 4.5 hours, for a total of 10 
doses (20 drops). Approximately 1 hour after the last dose, 
conjunctival irritation of the study eye was assessed using a 
slit-lamp biomicroscope to individually evaluate conjunctival 
congestion, swelling, and discharge, according to the Hackett 
and McDonald Scoring System (Table 1).16
Results
The mean conjunctival irritation scores are shown in Table 2. 
Approximately one hour after the last dose of bimatoprost 
ophthalmic solutions, mean conjunctival swelling was simi-
lar in both groups (0.33 ± 0.6), but both mean conjunctival 
congestion and discharge scores were higher for bimatoprost 
0.01% (2.00 ± 0.0 and 1.33 ± 0.6, respectively) than for bima-
toprost 0.03% (1.67 ± 0.6 and 0.33 ± 0.6, respectively).
Discussion
In this study, both formulations of bimatoprost caused mild 
to moderate conjunctival irritation in rabbits. After an exag-
gerated dosing of 20 drops over 4.5 hours, it was noted that 
congestion was the primary conjunctival toxicity caused by 
bimatoprost in this study, which is consistent with the safety 
profile of this agent in clinical studies.7,17–19
The conjunctival congestion and discharge scores 
observed after the last dose were higher for bimatoprost 
0.01% than for bimatoprost 0.03% (congestion: 2.00 vs 
1.67; and discharge: 1.33 vs 0.33). Thus, despite the reduced 
concentration of bimatoprost in the 0.01% formulation, no 
improvement in ocular toxicity scores was observed. While 
the number of animals per group was small, the individual 
animal responses within each group were similar, supporting 
this conclusion.
A potential explanation for these results may be related 
to the BAK concentrations present in the two bimatoprost 
formulations. Bimatoprost 0.03% contains one of the lowest 
levels of BAK typically used in ophthalmic preparations, 
0.005%, whereas bimatoprost 0.01% contains one of the 
highest levels, 0.02%. It is well established that BAK alone 
causes both corneal and conjunctival toxicity in preclinical 
testing;10–12,15,20,21 this same association between BAK and 
ocular toxicity is also observed when comparing BAK-
preserved to BAK-free topical ocular medications, either 
under in vitro conditions22–24 or using a rabbit model similar 
to the current study.25–31 Not surprisingly, clinical studies of 
patients with glaucoma have reported increased ocular toxic-
ity with medications containing BAK.14,32–34 Moreover, ocular 
surface effects caused by BAK are dose-dependent,11,12,21 




0 1 2 3 4
Congestion none Flushed reddish;  
slight perilimbal  
injection
Bright red; 75%  
perilimbal injection
Dark, beefy red; bulbar,  
palpebral, perilimbal  
injection; presence  
of petechia
n/Aa
swelling none swelling above  
normal with no  
lid eversion
swelling with  
misalignment of lids;  
upper  lower
swelling with  
partial eversion;  
upper = lower
Marked eversion;  
upper  lower
Discharge none Present on inner  
portion of eye
Abundant on lids  
and hair
Marked discharge  
on periocular skin
n/Aa
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which suggests that the higher concentration of BAK in bima-
toprost 0.01% may increase any BAK-associated toxicity. The 
European Medicines Agency (EMEA) has recognized the 
ocular surface effects of ophthalmic preservatives and rec-
ommends using preservative-free formulations or the lowest 
concentration of preservative with satisfactory antimicrobial 
effectiveness. Therefore, increasing the concentration of BAK 
by 4-fold in the bimatoprost 0.01% formulation, relative to 
the bimatoprost 0.03% formulation, is not in accordance 
with the EMEA’s position and has a negative impact on the 
benefit-to-risk ratio for the product.35
Due to the potential differences between rabbits and 
humans in response to BAK-induced ocular toxicity, the 
differences in the dosing methodology of this animal study 
as compared to dosing in a clinical setting, and the vary-
ing concentrations of bimatoprost, the two bimatoprost 
formulations investigated in this study should be evalu-
ated for both safety and efficacy in a randomized clinical 
trial. Nonetheless, the current study suggests that, despite 
its lower drug concentration, bimatoprost 0.01% does 
not reduce conjunctival irritation in rabbits compared to 
bimatoprost 0.03%.
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